Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

Cocrystal Pharma, Inc.

CIK 1412486 COCP·Pharmaceutical Preparations · All EDGAR filings ↗

Accounting standard newly cited Filing comparison

Cocrystal Pharma, Inc. cited accounting standard ASU 2023-09 for the first time in this filing series

Upon adoption of ASU 2023-09, Improvements to Income Tax Disclosures, the reconciliation of taxes at the federal statutory rate to our provision for (benefit from) income taxes for the year ended December 31,2025 was as follows (in thousands, except for percentages): Schedule of Reconciliation of Federal Statutory Income Tax Rate Year Ended December 31, 2025 Tax Computed at federal statutory rate…
Evidence
Adopted
2023-09
Contexts
Upon adoption of ASU 2023-09, Improvements to Income Tax Disclosures, the reconciliation of taxes at the federal statutory rate to our provision for (benefit from) income taxes for the year ended December 31,2025 was as follows (in thousands, except for percentages): Schedule of Reconciliation of Federal Statutory Income Tax Rate Year Ended December 31, 2025 Tax Computed at federal statutory rate…
New standards
2023-09
Prior filed
2025-03-31
Prior form
10-K
Restates existing policy
No
Source
accounting standards update (ASU) reference comparison
Why
An accounting standard (ASU) appears in this filing that did not appear in the previous comparable one, in a sentence describing it as adopted. That is a change in what the company discloses, which is not always a change of policy in the current period: the filing may state an adoption date years earlier.